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Purpose: To evaluate the prognostic significance of the depth of lamina propria invasion 
in primary T1 transitional cell carcinoma (TCC) of the bladder.
Materials and Methods: We retrospectively reviewed the medical records of 183 pa-
tients with primary T1 TCC of the bladder who had undergone transurethral resection 
(TUR) at our institution. Substaging was defined according to the depth of lamina prop-
ria invasion as follows: T1a, superficial invasion of lamina propria; T1b, invasion into 
the muscularis mucosa (MM); T1c, invasion beyond the MM but not to the muscularis 
propria. The prognostic significance of various clinicopathological variables for re-
currence and progression was analyzed.
Results: Of the 183 patients, substaging was T1a in 119, T1b in 57, and T1c in 7 patients. 
The recurrence rate was 32.8% for T1a and 40.6% for T1b/c, but there was no significant 
difference between the two groups. The progression rate was significantly different be-
tween the two groups: 5.8% in T1a and 21.9% in T1b/c (p=0.003). The cancer-specific 
mortality rate was also significantly different: 4.2% in T1a and 14.0% in T1b/c (p=0.036). 
In the univariate analysis, microscopic tumor architecture was the only significant 
prognostic factor for recurrence. In the univariate and multivariate analysis concern-
ing progression, depth of lamina propria invasion and concomitant carcinoma in situ
were significant prognostic factors.
Conclusions: Substaging according to the depth of lamina propria invasion in primary 
T1 TCC of the bladder was an independent prognostic factor for progression. This sug-
gests that substaging would be helpful for guiding decisions about adjuvant therapies 
and follow-up strategies.
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INTRODUCTION
Bladder cancer is the most common malignancy of the uri-
nary tract [1,2]. Approximately 75 to 85% of patients with 
bladder cancer are diagnosed as having as non-muscle-in-
vasive bladder cancer (NMIBC). In NMIBC, approxima-
tely 70% of patients present as pTa, 20% as pT1, and 10% 
as carcinoma in situ (CIS) [3]. Generally, 30 to 80% of 
NMIBC will recur and 1 to 45% of cases will progress to 
muscle-invasive bladder cancer within 5 years [4-6]. Of 
NMIBC, T1 transitional cell carcinoma (TCC) of the blad-
der with lamina propria invasion is known to have different 
degrees of aggressiveness, with a progression rate varying 
from 12 to 54% [7,8]. For T1 TCC of the bladder, it is im-
portant to select those patients who have a favorable prog-
nosis and those who are at high risk for progression. Thus, 
many clinical (age, gender, multifocality, tumor size) and 
pathologic (concomitant CIS, tumor grade, architecture) Korean J Urol 2012;53:317-323
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FIG. 1. Hematoxylin-eosin-stained paraffin sections of three distinct bladder cancers. (A) Ta; no invasion into the muscularis mucosa 
(MM) showing MM and muscularis propria (MP). (B) T1a; superficial invasion of the lamina propria. (C) T1b; invasion into the MM. 
(The tumor base limit is marked with an arrow).
factors for recurrence and progression have been ex-
tensively studied over the years to predict prognosis and 
guide management decisions [3,6].
Younes et al. [9] were the first to use the muscularis mu-
cosa (MM) in transurethrally resected biopsy specimens to 
substage T1 TCC of the bladder. The MM is a scattered 
muscular fiber that is formed as a continuous or inter-
rupted layer running along large blood vessels in the lami-
na propria between the epithelium and the detrusor 
muscle. Since that time, several studies have been con-
ducted to identify whether the depth of lamina propria in-
vasion is a valuable prognostic factor with the use of the 
MM as a landmark for substaging. Several reports have 
demonstrated a worse prognosis for T1 tumors with deep 
lamina propria invasion, with progression rates ranging 
from 29 to 55% [8-12]. However, Platz et al. [13] stated that 
substaging of early invasive bladder cancer is technically 
difficult and does not have additional prognostic value with 
respect to survival.
In this study, we retrospectively reviewed our sin-
gle-center experience in patients with primary T1 TCC of 
the bladder and evaluated the feasibility and the prog-
nostic significance of the depth of lamina propria invasion 
on recurrence and progression.
MATERIALS AND METHODS
Between January 1999 and December 2009, 651 patients 
underwent transurethral resection (TUR) procedures for 
bladder tumors at our institution. Among these patients, 
184 patients were diagnosed as having primary T1 TCC of 
the bladder and were followed up for at least 12 months. 
Of 184 patients, 1 patient who had an immediate radical 
cystectomy was excluded. Thus, the medical records of the 
remaining 183 patients (149 men and 34 women) were ret-
rospectively reviewed. The mean patient age was 63.5 
years (range, 27 to 93 years). None of the patients included 
in this study had an upper urinary tract malignancy at 
diagnosis. After TUR, all patients routinely received intra-
vesical bacillus Calmette-Guerin (BCG) instillation once 
per week for 6 weeks except for 3 patients. The first patient 
received Mitomycin-C owing to a previous operation his-
tory of kidney transplantation, the second patient had cur-
rent active pulmonary tuberculosis, and the third patient 
refused BCG therapy.
All TUR specimens from the routine histologic stains 
(hematoxylin-eosin) were reviewed again by one genito-
urinary pathologist. Substaging was defined according to 
the depth of lamina propria invasion by using the Younes 
et al. [9] classification as follows: T1a, invasion of the lami-
na propria superficial to the level of the MM; T1b, invasion 
to the level of the MM; T1c, invasion through the level of 
the MM but superficial to the muscularis propria (Fig. 1). 
When the MM could not be found and the vascular plexus 
was identified, it served as a marker of MM level [8,14]. 
Tumors were staged by using the 2002 tumor-node-meta-
stasis staging system [15] and were graded as high or low 
grade according to the 2004 World Health Organization/In-
ternational Society of Urological Pathology grading sys-
tem [16]. The microscopic tumor architecture was divided 
into papillary and solid. A solid growth pattern refers to a 
tumor that is composed of diffusely growing sheets of tumor 
cells without fibrovascular core formation. To classify a tu-
mor as solid, at least 10% of the components need to be 
judged as solid [17].
The median follow-up period was 36 months (mean, 43.5 
months; range, 12 to 146 months). Patients were followed 
until death or last visit and the follow-up included uri-
nalysis, cystoscopy, and urine cytology every 3 months for 
the first 2 years, every 6 months for the subsequent 2 years, 
and then annually thereafter. Abdominopelvic computed 
tomography was performed annually during the follow-up 
or when clinically indicated.
Clinical outcome was evaluated in terms of tumor re-Korean J Urol 2012;53:317-323
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TABLE 1. Patient characteristics of the 183 patients included in 
the study
Characteristic No. of cases (%)
Age (yr)
≤65
＞65
Gender
Male
Female
Multifocality
Single
Multiple
Tumor size (cm)
＜3
≥3
Concomitant CIS
No
Yes
Tumor grade
Low
High
Microscopic tumor architecture
Papillary
Solid
Depth of invasion
T1a
T1b
T1c
Radical cystectomy after TUR
Recurrence
Progression
Death
Death of disease
Death of other diseases
  92 (50.3)
  91 (49.7)
149 (81.4)
  34 (18.6)
  96 (52.5)
  87 (47.5)
  98 (53.6)
  85 (46.4)
119 (65.0)
  64 (35.0)
12 (6.6)
171 (93.4)
175 (95.6)
  8 (4.4)
119 (65.0)
  57 (31.1)
  7 (3.9)
  8 (4.4)
  65 (35.5)
  21 (11.4)
13 (7.1)
  8 (4.3)
CIS, carcinoma in situ; TUR, transurethral resection.
TABLE 2. Analysis of clinicopathological factors influencing 
recurrence
Variable
No. of 
recurrence 
(%)
No. of 
recurrence-
free (%)
p-value
Gender
Male
Female
Multifocality
Single
Multiple
Tumor size (cm)
＜3
≥3
Concomitant CIS
No
Yes
Tumor grade
Low
High
Microscopic tumor 
architecture
Papillary
Solid
Depth of invasion
T1a
T1b/c
52 (35.3)
13 (38.2)
31 (33.0)
34 (39.1)
34 (34.7)
31 (37.2)
37 (31.7)
28 (43.8)
  2 (16.7)
63 (37.2)
59 (34.1)
  6 (75.0)
39 (33.3)
26 (40.6)
  97 (64.7)
  21 (61.8)
  65 (67.0)
  53 (60.9)
  64 (65.3) 
  54 (62.8)
  82 (68.3)
  36 (56.2)
  10 (83.3)
108 (62.8)
116 (65.9)
    2 (25.0)
  80 (66.7)
  38 (59.4)
0.843
0.442
0.759
0.110
0.217
0.026
0.338
CIS, carcinoma in situ.
currence or progression. Recurrence was defined as the his-
tological detection of TCC of the bladder through TUR or 
bladder biopsy after the first TUR. Progression was defined 
as the development of muscle-invasive disease or distant 
metastasis. The diagnosis of an advanced tumor of the up-
per urinary tract was not considered as progression [8,17].
Univariate and multivariate analyses were performed 
by using the log-rank test or the Cox’s proportional hazards 
regression model, respectively. The association between 
recurrence or progression and clinicopathological factors 
and the relationship between substaging and other prog-
nostic parameters were examined by using the chi-square 
test. The prognostic parameters assessed were clinical 
(gender, multifocality, and tumor size) and pathologic 
(concomitant CIS, tumor grade, microscopic tumor archi-
tecture, and substaging) factors. All statistical analyses 
were performed by using SPSS ver. 13.0 (SPSS Inc., 
Chicago, IL, USA). Values of p＜0.05 were considered to be 
statistically significant in all of the analyses.
RESULTS
The clinicopathological characteristics of the 183 patients 
with primary T1 TCC of the bladder are summarized in 
Table 1. The number of tumors was 2 or more in 87 cases 
(47.5%), the mean number of tumors was 2.1 (range, 1 to 
9), and tumor size was 3 cm or more in 85 cases (46.4%). 
Concomitant CIS was present with the main tumor in 64 
cases (35.0%), a high grade of tumor was found in 171 cases 
(93.4%), and the microscopic tumor architecture was of the 
papillary growth pattern in 175 cases (95.6%). Substaging 
was possible in all 183 cases. Substaging was as follows: 
T1a in 119 (65.0%), T1b in 57 (31.1%), and T1c in 7 (3.9%). 
Eight patients (4.4%) underwent radical cystectomy after 
TUR owing to frequent recurrence or progression.
To evaluate the risks of recurrence and progression, T1b 
and T1c tumors were pooled together because only 7 cases 
had T1c tumors. The recurrence rate was 32.8% (39/119) 
for T1a and 40.6% (22/57 for T1b and 4/7 for T1c) for deep 
lamina propria-invasive tumors including T1b and T1c 
(T1b/c) during the follow-up period, which was not sig-
nificantly different (p=0.338) (Table 2). The overall re-
currence rate was 35.5% (65/183). The average period until 
the first recurrence was 16.3 months (range, 1 to 77 mon-
ths) and the mean number of recurrences was 1.5 times 
(range, 1 to 4 times). The progression rate was significantly 
higher in patients with deep lamina propria invasion Korean J Urol 2012;53:317-323
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TABLE 3. Analysis of clinicopathological factors influencing 
progression
Variable
No. of 
progression 
(%)
No. of 
progression-
free (%)
p-value
Gender
Male
Female
Multifocality
Single
Multiple
Tumor size (cm)
＜3
≥3
Concomitant CIS
No
Yes
Tumor grade
Low
High
Microscopic tumor 
architecture
Papillary
Solid
Depth of invasion
T1a
T1b/c
15 (10.0)
  6 (17.6)
8 (8.2)
13 (14.9)
8 (8.2)
13 (15.1)
9 (7.5)
12 (18.8)
0 (0)
21 (12.2)
20 (11.4)
  1 (12.5)
7 (5.8)
14 (21.9)
134 (90.0)
  28 (82.4)
  88 (91.8)
  74 (85.1)
  90 (91.8)
  72 (84.9)
110 (92.5)
  52 (81.2)
12 (100)
150 (87.8)
155 (88.6)
    7 (87.5)
112 (94.2)
  50 (78.1)
0.232
0.170
0.166
0.029
0.366
0.921
0.003
CIS, carcinoma in situ.
FIG. 2. Kaplan-Meier estimates of recurrence-free (A) and progression-free (B) survival according to the depth of lamina propria 
invasion in primary T1 transitional cell carcinoma (TCC) of the bladder. Whereas the recurrence-free interval was similar for both 
groups, the progression-free interval was significantly shorter in patients with T1b/c compared with T1a tumors.
(p=0.003): 5.8% (7/119) in T1a and 21.9% (14/57 for T1b and 
0/7 for T1c) in T1b/c (Table 3). The overall progression rate 
was 11.5% (21/183). The average period until the first pro-
gression was 18.3 months (range, 4 to 69 months). Recur-
rence and progression rates were not significantly differ-
ent between low- and high-grade lesions in T1a tumors 
(p=0.190 and p=0.361, respectively), and those variables 
could not be compared between low- and high-grade T1b/c 
tumors because there were no low-grade lesions in T1b/c 
tumors.
The cancer-specific mortality rate was also significantly 
higher in patients with deep lamina propria invasion 
(p=0.036): 4.2% (5/119) in T1a and 14.0% (8/64) in T1b/c. 
Eight patients died of unrelated causes, giving an overall 
mortality rate of 11.5% (21/183). Tables 2 and 3 summarize 
the analysis of the clinicopathological factors influencing 
recurrence and progression. According to the Kaplan-Meier 
analysis, the progression-free interval was significantly 
shorter in patients with T1b/c tumors than in those with 
T1a tumors (p=0.001). The recurrence-free interval, in con-
trast, was similar for both groups (p=0.235). Curves for pro-
gression-free and recurrence-free estimates are plotted in 
Fig. 2.
In the univariate analysis of prognostic factors influenc-
ing recurrence, microscopic tumor architecture was the on-
ly significant prognostic factor for recurrence (p=0.029). 
However, it was not statistically significant in the multi-
variate analysis (p=0.075). Also, the depth of lamina prop-
ria invasion was not a statistically significant prognostic 
factor influencing recurrence in either the univariate or the 
multivariate analysis (p=0.235, p=0.797, respectively) 
(Table 4).
In the univariate and multivariate analyses concerning 
progression, depth of lamina propria invasion was a stat-
istically significant prognostic factor (p=0.001 and p=0.006, 
respectively) and the presence of concomitant CIS was also 
an independent prognostic factor (p=0.026 and p=0.047, re-
spectively) (Table 5).
The correlation between T1 substaging and other prog-
nostic parameters was evaluated (Table 6). Multifocality, 
tumor size, and presence of concomitant CIS were similar 
in the two groups. However, high tumor grade was sig-
nificantly more frequent in the T1b/c group (p=0.009) and 
a microscopic solid growth pattern was also significantly Korean J Urol 2012;53:317-323
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TABLE 6. Relationship between T1 substaging and other prognostic parameters
Stage
Multifocality Tumor size (cm) Concomitant CIS Tumor grade
Microscopic tumor 
architecture
Single Multiple ＜3 ≥3 No Yes Low High Papillary Solid
T1a
T1b/c
63
33
56
31
66
32
53
32
36
27
83
37
12
  0
107
  64
118
  57
1
7
p-value 0.877 0.538 0.145 0.009 0.003
CIS, carcinoma in situ.
TABLE 4. Univariate and multivariate analysis of prognostic factors influencing recurrence
Variable
Univariate Multivariate
p-value Hazards ratio (95% CI) p-value
Gender (male vs. female)
Multifocality (single vs. multiple)
Tumor size (＜3 cm vs. ≥3 cm)
Concomitant CIS (no vs. yes)
Tumor grade (low vs. high)
Microscopic tumor architecture (papillary vs. solid)
Depth of invasion (T1a vs. T1b/c)
0.910
0.485
0.688
0.078
0.141
0.029
0.235
1.087 (0.582-2.029)
1.048 (0.633-1.736)
1.271 (0.766-2.107)
1.473 (0.870-2.492)
0.444 (0.105-1.876)
2.282 (0.920-5.659)
1.072 (0.631-1.821)
0.793
0.855
0.353
0.141
0.269
0.075
0.797
CI, confidence interval; CIS, carcinoma in situ.
TABLE 5. Univariate and multivariate analysis of prognostic factors influencing progression
Variable
Univariate Multivariate
p-value Hazards ratio (95% CI) p-value
Gender (male vs. female)
Multifocality (single vs. multiple)
Tumor size (＜3 cm vs. ≥3 cm)
Concomitant CIS (no vs. yes)
Tumor grade (low vs. high)
Microscopic tumor architecture (papillary vs. solid)
Depth of invasion (T1a vs. T1b/c)
0.240
0.165
0.148
0.026
0.197
0.894
0.001
1.760 (0.672-4.612)
1.577 (0.643-3.869)
2.251 (0.909-5.572)
2.561 (1.013-6.473)
0
0.402 (0.049-3.304)
2.009 (1.024-3.942)
0.250
0.320
0.079
0.047
0.985
0.396
0.006
CI, confidence interval; CIS, carcinoma in situ.
more frequent in the T1b/c group (p=0.003).
DISCUSSION
The presence of MM in the lamina propria was first re-
ported by Dixon and Gosling [18] from the biopsy specimens 
of 25 patients and the radical cystectomy specimens of 4 pa-
tients in 1983. The use of MM to substage T1 TCC of the 
bladder was first described by Younes et al. [9]. Since then, 
several studies about the MM have been conducted to iden-
tify prognostic significance. The results of the present 
study show that the depth of lamina propria invasion is a 
significant predictor of progression in patients with pri-
mary T1 TCC of the bladder, with a 21.9% progression rate 
for T1 tumors deeply invading the lamina propria (T1b/c) 
as opposed to a 5.8% progression rate for T1 tumors without 
deep lamina propria involvement (T1a). In other previous 
studies, the progression rates for T1 tumors deeply invad-
ing the lamina propria (T1b/c) were shown to be at least 29% 
and up to 55% [12,19], which is similar to the results of our 
study. In contrast, progression rates for T1a, i.e., those with 
limited invasion, ranged from at least 6.7% and up to 11% 
[8,20], which is also similar to the 5.8% in our study. In the 
previous Korean study, Kim et al. [21] reported similar re-
sults showing that the progression rate of T1b/c tumors was 
significantly higher than that of T1a tumors (41.4% and 
3.8%, respectively). Shin et al. [22] reported that pro-
gression rates of T1a, T1b, and T1c tumors were 0%, 10%, 
and 20.6%, respectively (p=0.005). Kim et al. [23] also re-
ported statistically significant results showing that the 
2-year risk of progression of T1a, T1b, and T1c tumors was 
5%, 19%, and 33%, respectively. The higher progression 
rate of patients with deep lamina propria invasion may be 
due to the increased risk of lymphatic permeation, because Korean J Urol 2012;53:317-323
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the lamina propria is richly supplied with lymphatics [10]. 
Regarding cancer-specific mortality, it was also sig-
nificantly different between the two groups: 4.2% in T1a 
and 14.0% in T1b/c in this study. Among different series, 
survival rates have ranged from at least 58% and up to 95% 
for T1a and between 11% and 82% for T1b/c [9-11], which 
is similar to the results of our study.
Even though the depth of lamina propria invasion has 
consistently remained the most important factor related to 
progression in primary T1 TCC of the bladder, both the use-
fulness and the effectiveness of T1 substaging have been 
debated by pathologists. The criticisms include difficulty 
in identifying the MM and interpathologist variation and 
disagreement. These difficulties are thought to be due to 
uneven distribution, misorientation, or thermal injury of 
resection fragments [8,13]. However, Orsola et al. [8] sug-
gested that they could be overcome through practice and 
reported that the identification rate of MM progressed from 
an initial 60% to an 87% rate at present, with a progressive 
decrease in interpretative discrepancies. Similarly, in pre-
vious publications, the rate of substaging has increased 
from the initial 65 to 72% to up to 100% in more recent re-
ports [24,25]. Surgical technique is also important to im-
prove substaging. Methods that enable pathologists to 
have a better opportunity for identifying MM include mini-
mizing cautery artifacts when performing TUR of bladder 
tumors to obtain good TUR specimens, submitting the tu-
mor base separately, and focusing on fragment direction 
to avoid artifacts [8,26]. In difficult cases in which specimen 
orientation and artifacts could create a major hindrance, 
Mhawech et al. [27] reported that immunohistochemistry 
using desmin and keratin in comparison to hematox-
ylin-eosin was superior in lowering the rate of imprecision 
and appeared to be a useful tool in substaging. They also 
reported that the combination of p21 and p16 may have val-
ue in distinguishing T1b tumors from T1a tumors through 
the study of molecular markers [28]. Therefore, the accu-
racy of T1 substaging could be improved through the prac-
tice and experience of the pathologist, by immunohi-
stochemistry, and through the expression of molecular 
markers.
In previous studies, some authors claimed that T1b and 
T1c tumors might be pooled together to improve sub-
categorization, because T1b and T1c tumors show an al-
most identical clinical behavior [8,10,11,20,24]. Thus, it 
may be reasonable to categorize tumors with deep lamina 
propria involvement invading to or through the level of the 
MM or vascular plexus in the lamina propria as one 
category. In our study, T1b and T1c tumors were pooled to-
gether and T1b/c was used to evaluate the prognostic 
significance.
Concomitant CIS has been reported to have a negative 
effect on prognosis and is a well-known risk factor for re-
currence and progression [29,30]. Orsola et al. [8] showed 
that the depth of lamina propria invasion and associated 
CIS were significant prognostic factors in patients receiv-
ing BCG therapy. Similarly, Bernardini et al. [24] reported 
that tumors invading the MM associated with CIS had a 
risk of progression increased by a factor of 7.5. Smits et al. 
[12] reported a 3-year progression rate of 39% in patients 
with CIS compared with 9% among patients without CIS. 
The present study also showed that the presence of con-
comitant CIS was a significant predictive factor for pro-
gression, with an increased hazards ratio in the multi-
variate analysis.
This study had several limitations. First, this study was 
conducted in a single center. Second, treatment was not 
identical for all patients, because TUR was not conducted 
by a single surgeon. Third, interpathologist variation and 
disagreement could not be evaluated, because all the TUR 
specimens were reviewed and diagnosed by one patholo-
gist. Fourth, the study was retrospective in nature and the 
size of the study population was small. Fifth, second re-
sections were not routinely performed. Nevertheless, we 
believe that the results of our study support that the pa-
tients with deep lamina propria invasion (T1b/c) have a sig-
nificantly higher progression rate, especially those with 
concomitant CIS, which is also an independent predictor 
of progression. In addition, designing multicenter and 
randomized prospective trials including biological mark-
ers might contribute to determining the optimal treatment 
for deep lamina propria-invasive T1 bladder cancer.
CONCLUSIONS
The results of this study demonstrated that substaging ac-
cording to the depth of lamina propria invasion in primary 
T1 TCC of the bladder and the presence of concomitant CIS 
were independent prognostic factors for progression and 
that the patients with deep lamina propria invasion had 
a significantly higher cancer-specific mortality rate. These 
findings will be helpful for guiding decisions about ad-
juvant therapies such as more radical treatment and the 
follow-up strategies after TUR of bladder tumors.
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